Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2015 - 20203

Settings

Has files: NoSubject: search.filters.subject.Biomarker

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Effect of Left Ventricular Assist Devices on Red Blood Cell Distribution Width
    (2015) Ersoy, Ozgur; Gultekin, Bahadir; Ozkan, Murat; Akkaya, Ilknur; Umaroglu, Sevi; Sezgin, Atilla; 26640934; ABA-7388-2021
    Objectives: Red blood cell distribution width is a measure of the variability in the size of circulating erythrocytes, which is calculated by automated blood cell counters as part of a routine blood cell count analysis. Our aim was to examine whether continuous flow left ventricular assist devices affected red blood cell distribution width. Materials and Methods: Our study included 16 of 24 patients who received a HeartWare HVAD Pump (HeartWare Inc, Framingham, MA, USA) implant (continuous flow left ventricular assist device) between April 2012 and February 2015 at our institution. The mean age of the patients was 46.6 years. We compared patient erythrocyte, leucocyte, and platelet counts, hemoglobin and hematocrit levels, mean corpuscular volume, and red blood cell distribution width values before and 6 months after implant. Results: Hemoglobin level (P=.008), hematocrit level (P=.027), and mean corpuscular volume (P=.003) were significantly decreased; however, we observed no significant change in red blood cell distribution width. Conclusions: Although we did not find significant results in our group of patients with left ventricular assist device implant, a larger group of patients may show more significant results, and an increase in red blood cell distribution width can be used as an indicator of a negative prognosis in these patients.
  • No Thumbnail Available
    Item
    Serum and placental periostin levels in women with early pregnancy loss
    (2020) Eroglu, Semra; Colak, Eser; Erinanc, Ozgur Hilal; Ozdemir, Duygu; Ceran, Mehmet Ufuk; Tasdemir, Umit; Kulaksizoglu, Sevsen; Ozcimen, Emel Ebru; 0000-0003-1401-6356; 0000-0002-7613-2240; 0000-0002-9959-9433; 32460058; AAL-1268-2021; AAI-8932-2021
    Objectives: Periostin is secreted from the placenta in the embryonic period and it is emphasized that it may be involved in endometrial implantation. In this study, we aimed to investigate periostin serum levels and placental tissue expression in first trimester pregnancy losses. Study design: In this prospective case-control study, 30 patients who underwent dilatation and curettage with first trimester spontaneous abortion (< 10 weeks of gestation) were included in the study group and 30 patients who had voluntary pregnancy termination (< 10 gestational weeks) were included in the control group. Serum samples collected from the study and control groups were analyzed usingenzyme-linkedimmunosorbent assay (ELISA), and trophoblastic and decidual tissues were examined using immunohistochemical staining with streptavidin-biotin-peroxidase techniques. Results: There were no significant differences between the groups in terms of age, gravida status, parity number, gestational week, and number of previous abortions. In the spontaneous abortion group, the serum level of periostin was significantly lower than in the voluntary termination group (6.56 +/- 4.16 pg/mLvs. 9.51 +/- 4.52 pg/mL, p = 0.03). There was no significant difference between the two groups in terms of periostin expression in decidual and trophoblastic tissue (p = 0.617, p = 0.274, p = 0.497). Conclusion: Periostin serum levels were significantly reduced in patients with spontaneous pregnancy loss. Periostin can be used as a predictive marker for the success of endometrial implantation.
  • No Thumbnail Available
    Item
    Effect of platelet-rich plasma on serum and urine biomarkers in patients with knee osteoarthritis
    (2020) Kuculmez, Ozlem; Sirin, Fevziye Burcu; Sarikaya, Nese Olmez; Kocyigit, Hikmet; 0000-0002-8900-0060; AAM-4037-2021
    Background: Biomarkers may reflect changes in cartilage metabolism and could be used in diagnosis and evaluation of treatment response in knee osteoarthritis. The aim of this study is to determine the effect of platelet rich plasma (PRP) injections on serum and urine biomarkers in patients with knee osteoarthritis (OA). Methods: The study included 26 patients who were diagnosed as grade III knee OA according to ACR criteria and Kellgren-Lawrence classification. One cc of PRP was obtained from 20 cc of venous blood after double centrifugations at 400 g for 10 minutes. The patients received 3 injections of PRP at 3-weeks intervals. Serum Procollagen II N-terminal propeptide (PIINP), osteocalcin (OC), cartilage oligomeric matrix protein (COMP) and urine collagen-II telopeptide (U-CTX-II) were examined in all patients before treatment and at 3 and 6 months. Clinical outcome was evaluated using Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire, SF-36 and visual analog scale (VAS) in all patients before injection and at 3 and 6 months follow-up visits. Results: There was no statistically significant difference in cartilage Type II collagen (CII) degradation markers (CTX-II, COMP) and biosynthesis marker of PIINP (P>0.05). Significant increase was determined in serum OC levels (P<0.05) which reflects CII biosynthesis. Statistically significant improvement in all WOMAC parameters (P<0.05) and subscores of SF-36 (P<0.05) was noted. Conclusion: We found significant clinical improvements in knee OA patients treated with PRP injections. Our results suggest that PRP injection does not affect cartilage breakdown but effects CII biosynthesis, which is reflected by increased OC levels. However further studies are needed.